Innate Pharma S.A. (IPHYF)
USD 2.9
(0.0%)
USD 2.9
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 51.9 Million | 49.63 Million | 12.11 Million | 56.83 Million | 68.97 Million | 79.89 Million |
| Cost of Revenue | 56.02 Million | 51.66 Million | 47 Million | 3.04 Million | 45.15 Million | 69.55 Million |
| Gross Profit | -4.12 Million | -2.02 Million | -34.89 Million | 53.79 Million | 23.81 Million | 10.33 Million |
| Operating Expenses | 64.57 Million | 66.06 Million | 59.93 Million | 75.38 Million | 50.86 Million | 74.74 Million |
| Selling, General and Administrative Expenses | 11.74 Million | 22.43 Million | 25.52 Million | 30.38 Million | 49.58 Million | 19.25 Million |
| Research and Development Expenses | 56.02 Million | 51.66 Million | 47 Million | 58.61 Million | 1.59 Million | 69.55 Million |
| Other Expenses | -56.02 Million | - | - | - | - | - |
| Cost and Expenses | 64.57 Million | 66.06 Million | 59.93 Million | 75.38 Million | 96.02 Million | 74.74 Million |
| Operating Income | -12.66 Million | -57.42 Million | -47.82 Million | -62.07 Million | -27.05 Million | 5.14 Million |
| Interest Expense | 640 Thousand | 5.32 Million | 3.99 Million | 6.76 Million | 204 Thousand | 102 Thousand |
| Income Tax Expense | - | 5.45 Million | 13.65 Million | 6.76 Million | 206 Thousand | -333 Thousand |
| Earnings before Tax | -7.57 Million | -57.97 Million | -45.47 Million | -63.98 Million | -20.75 Million | 2.71 Million |
| Net Income | -7.57 Million | -58.1 Million | -52.8 Million | -63.98 Million | -20.75 Million | 3.04 Million |
| Earnings Per Share Basic | -0.09 | -0.73 | -0.66 | -0.81 | -0.31 | 0.05 |
| Earnings Per Share Diluted | -0.09 | -0.73 | -0.66 | -0.81 | -0.31 | 0.05 |
| Weighted Average Shares Outstanding | 80.45 Million | 79.63 Million | 79.54 Million | 78.93 Million | 66.9 Million | 58.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 80.45 Million | 79.63 Million | 79.54 Million | 78.93 Million | 66.9 Million | 58.77 Million |
| Gross Margin | -0.08 | -0.04 | -2.88 | 0.95 | 0.35 | 0.13 |
| EBIT Margin | -0.04 | 0.68 | -3.05 | 0.76 | -0.13 | 0.15 |
| Profit Margin | -0.15 | -1.17 | -4.36 | -1.13 | -0.30 | 0.04 |
| EBITDA | -1.83 Million | -57.42 Million | -43.22 Million | 13.3 Million | 17.25 Million | 12.48 Million |
| Earnings Before Tax Margin | -0.24 | -1.16 | -3.95 | -1.09 | -0.39 | 0.06 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 6.17 Million | 6.17 Million | 51.9 Million | 10.72 Million | 10.72 Million | 35.34 Million |
| Cost of Revenue | 14.53 Million | 14.53 Million | 56.02 Million | 12.28 Million | 12.28 Million | 15.72 Million |
| Gross Profit | -8.36 Million | -8.36 Million | -4.12 Million | -1.56 Million | -1.56 Million | 19.61 Million |
| Operating Expenses | 4.79 Million | 4.79 Million | 69.21 Million | 4.57 Million | 4.02 Million | 36.95 Million |
| Selling, General and Administrative Expenses | 4.79 Million | 4.79 Million | - | 4.57 Million | 4.57 Million | 8.54 Million |
| Research and Development Expenses | 14.53 Million | 14.53 Million | - | 12.28 Million | 12.28 Million | 28.4 Million |
| Other Expenses | -14.53 Million | -14.53 Million | - | -12.28 Million | - | - |
| Cost and Expenses | 19.32 Million | 19.32 Million | 74.31 Million | 16.85 Million | 16.31 Million | 40.59 Million |
| Operating Income | -13.15 Million | -13.15 Million | -22.4 Million | -6.13 Million | -6.13 Million | -5.25 Million |
| Interest Expense | - | - | 640 Thousand | 1.51 Million | - | 324 Thousand |
| Income Tax Expense | - | - | -9.72 Million | -4.87 Million | - | -4.85 Million |
| Earnings before Tax | -12.38 Million | -12.38 Million | -17.29 Million | -4.64 Million | -4.64 Million | -3.13 Million |
| Net Income | -12.38 Million | -12.38 Million | -7.57 Million | -4.64 Million | -4.64 Million | 1.71 Million |
| Earnings Per Share Basic | -0.15 | -0.15 | - | -0.06 | -0.06 | 0.02 |
| Earnings Per Share Diluted | -0.15 | -0.15 | - | -0.06 | -0.06 | 0.02 |
| Weighted Average Shares Outstanding | 79.88 Million | 79.88 Million | 80.45 Million | 80.58 Million | 80.58 Million | 80.31 Million |
| Weighted Average Shares Outstanding (Diluted) | 80.87 Million | 80.87 Million | 80.45 Million | 80.58 Million | 80.58 Million | 83.78 Million |
| Gross Margin | -1.36 | -1.36 | -0.08 | -0.15 | -0.15 | 0.56 |
| EBIT Margin | -2.07 | -2.07 | - | -0.48 | -0.48 | -0.05 |
| Profit Margin | -2.01 | -2.01 | -0.15 | -0.43 | -0.43 | 0.05 |
| EBITDA | -12.78 Million | -12.78 Million | - | -5.19 Million | -5.19 Million | -1.6 Million |
| Earnings Before Tax Margin | -2.13 | -2.13 | -0.43 | -0.57 | -0.57 | -0.15 |
CVLT
0HC2
7218
GYRE
CBDHF
002329